摘要
卵巢透明细胞癌(OCCC)是上皮性卵巢癌的一种特殊组织学类型,对传统的化疗方案耐药,预后不良,寻找新的靶向治疗方案迫在眉睫。磷脂酰肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶体蛋白(PI3K/AKT/m TOR)信号通路在卵巢癌的发生和发展中发挥重要作用,并且与化疗耐药密切相关。该通路的活化不但可以抑制细胞凋亡,促进细胞增殖,还参与肿瘤的侵袭与转移。在OCCC中,PI3K/AKT/m TOR信号通路中的多种蛋白表达异常,该通路中的受体及激酶可能成为治疗OCCC的潜在靶点。现有研究表明PI3K/AKT/m TOR通路抑制剂不仅能增加紫杉醇或顺铂的细胞毒性效应,还可影响OCCC细胞系的生长情况。特别是OCCC中最常见的AT丰富结合域1A(ARID1A)突变与PI3K/AKT/m TOR信号通路关系十分密切。因此,针对PI3K/AKT/m TOR信号通路开发新的靶向治疗药物可能对OCCC的治疗具有一定意义。综述该通路与OCCC的关系,以期为探索新的靶向治疗提供理论基础。
Ovarian clear cell carcinoma（OCCC） is a special histological subtype of epithelial ovarian cancer, and presents resistant to the traditional chemotherapy on-hand, resulting in poor prognosis, so looking for a novel targeted therapy is extremely urgent. PI3K/AKT/m TOR pathway plays a significant role in the process of occurrence and development of ovarian cancer, and is intimately related to the resistance of chemotherapy. The suppression of apoptosis, the promotion of cell proliferation and the migration of tumor can be enforced by the pathway activation. The various proteins in PI3K/AKT/m TOR pathways express anomaly in the OCCC frequently, and thus the special receptor and kinase of the pathway could be a potential target for the therapy of ovarian clear cell carcinoma. The increasing of paclitaxel or cis-platinum cytotoxic effection and the growth of OCCC are in touch with PI3K/AKT/m TOR pathways in available studies. As the most frequent mutation in OCCC, ARID1 A is especially related to PI3K/AKT/m TOR pathways. Therefore, to search for novel targeted drug to the pathway may benefit the treatment of OCCC to some extent. To lay a theory fundation of the new targeted treatment, the relationship of this pathway and OCCC will be interpreted in this paper.
出处
《国际妇产科学杂志》
CAS
2015年第5期564-567,共4页
Journal of International Obstetrics and Gynecology
